

MEDIA RELEASE - COMMUNIQUE AUX MEDIAS - MEDIENMITTEILUNG

Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions

Schlieren (Zurich), Switzerland, April 22, 2010 – Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Annual Shareholders' Meeting 2010.

The Annual Shareholders' Meeting of Cytos Biotechnology took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 62 shareholders. 1,558,265 shares or 29.57% of a total of 5,270,056 shares were represented.

About Cytos Biotechnology

Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a diversified pipeline of Immunodrug™ candidates in various disease areas, of which six are currently in clinical development. The Immunodrug™ candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich, the Company is located in Schlieren (Zurich). Currently, the Company has 82 full-time employees. Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

For further information please contact:

Cytos Biotechnology Ltd

Jakob Schlapbach, MBA

Chief Financial Officer

Tel.: +41 44 733 46 46

Fax: +41 44 733 47 02

e-Mail: jakob.schlapbach@cytos.com

Website: www.cytos.com

This foregoing press release may contain forward-looking statements that include words or phrases such as “are intended for”, “are designed to” or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.